Cornerstone Capital Management Holdings’s Travere Therapeutics TVTX Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-47,000	Closed	-$1.05M	–	1419
2016 Q3	$1.05M	Buy	47,000 +39,100	+495%	+$744K	0.01%	933
2016 Q2	$141K	Sell	7,900 -110,298	-93%	-$1.79M	﹤0.01%	1245
2016 Q1	$1.61M	Buy	118,198 +26,777	+29%	+$406K	0.01%	805
2015 Q4	$1.76M	Buy	91,421 +85,521	+1,450%	+$1.71M	0.01%	767
2015 Q3	$120K	Buy	5,900 +5,000	+556%	+$148K	﹤0.01%	1310
2015 Q2	$30K	Buy	+900	New	+$24.6K	﹤0.01%	1379

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornerstone Capital Management Holdings's TVTX Position: Q4 2016 in Review

Cornerstone Capital Management Holdings sold out of Travere Therapeutics (TVTX) in Q4 2016, closing a stake of 47,000 shares — an estimated $1.05M sold.

Cornerstone Capital Management Holdings first reported a position in TVTX in Q2 2015 and held it in 6 quarters. The position peaked at $1.76M in Q4 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

Cornerstone Capital Management Holdings reported no remaining Travere Therapeutics position as of Q4 2016 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 47,000 Travere Therapeutics shares in Q4 2016, an estimated $1.05M.
Cornerstone Capital Management Holdings first reported a position in Travere Therapeutics in Q2 2015 and held it in 6 quarters.
Cornerstone Capital Management Holdings's Travere Therapeutics position peaked at $1.76M in Q4 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.